$VCYT

Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.

Veracyte's Prosigna test for early-stage breast cancer received Medicare coverage, enabling reimbursement for eligible patients. The test helps determine chemotherapy necessity, sparing over two-thirds of high-risk patients, per the OPTIMA trial. Veracyte (VCYT) aims for broader adoption and access.

ARK ETFs bought shares of Rocket Lab (RKLB), BWX Technologies (BWXT), Intellia Therapeutics (NTLA), and Veracyte (VCYT), while selling shares of Alphabet (GOOGL), Palantir (PLTR), and Zillow (Z). The transactions reflect ARK's strategy of investing in high-growth sectors and trimming positions in established tech companies.

ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).

ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.

ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the

ARK Invest, led by Cathie Wood, bought shares of Robinhood Markets (HOOD) and the 3iQ Solana Staking ETF (SOLQ.U) amid a market selloff triggered by strong U.S. jobs data, raising expectations of a Fed rate hike. ARKG added 28,589 HOOD shares ($3.49M) and 3,392 SOLQ.U shares ($28,120). The Dow, S&P 500, and Nasdaq fell 0.51%, 0.38%, and 0.29% respectively.

Febbo Phillip G. (Chief Scientific & Med Officer) sold 13,110 shares of VERACYTE, INC. (VCYT) at an average of $43.05 ($42.89–$43.66, $0.56M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS